MedTrace Logo

Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease

NCT04179201 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2019-11-27

No results posted yet for this study

Summary

In recent years, the incidence of Inflammatory Bowel Disease (IBD) has been increasing in China, which poses great challenges and burdens to the medical community due to its unknown etiology, recurrence and incurability. Co-infection is one of the important causes in IBD development. IBD accompanied with Clostridium Difficile Infection (CDI) can significantly decrease the treatment efficiency, leading to increased surgical rate, increased mortality, prolonged hospital stay, and increased hospital costs. Recently, several Chinese clinical guidelines about IBD or CDI have been published, but these guidelines are mainly based on the foreign studies. Compared with the developed countries, the lack of multi-center, large-scale and multi-test clinical trials and cohort studies caused limited understanding for IBD-CDI in China. Therefore, it is of great importance to carry out the multi-center clinical trials and analysis on IBD-CDI to improve the diagnostic and therapeutic efficiency in IBD-CDI patients

Objective:

1. To evaluate the prevalence rate of IBD-CDI in Chinese adults in China based on the multi-center clinical trials..
2. To analyze the related risk factors of IBD-CDI in China based on the multi-center clinical trials.
3. To analyze the intestinal flora of IBD-CDI patients via high-throughput sequencing.

Conditions

  • Inflammatory Bowel Diseases
  • Clostridium Infections

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Kaichun Wu, PhD · Chief Professor of Xijing Hospital

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-09-13
Primary Completion
2020-01-31
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04179201 on ClinicalTrials.gov